Bionure is a clinical stage R&D company developing first-in-class small molecule drug candidates for the treatment of neurodegenerative diseases, that benefit from treatment options with limited efficacy.
Our lead candidate, BN201, has shown compelling evidence of neuroprotective and remyelinating activity in several animal models and is completing a Phase 1 clinical study.
The next step of development will be to initiate an efficacy proof-of-concept Phase 2 clinical trial with BN201 in patients suffering from neurodegenerative diseases with high unmet needs, such as acute optic neuritis, a rare ophthalmological disease for which BN201 has been granted orphan drug status both in Europe and in the USA, and multiple sclerosis.
To guide our development efforts, we have built an extraordinary team of experts in neuro-ophthalmology and neuro-inflammation, committed and passionate about bringing meaningful therapies to society with the aim of changing the life of people enduring disabilities related to neurodegeneration.
The company was founded in 2009 as an academic spin-off from the Hospital Clinic of Barcelona (Spain) and further developed into a small R&D drug company. In 2018 Bionure strengthened its initial and solid shareholder base of business angels and family offices to welcome a first Venture Capital investor, Alta Life Sciences, a solid pillar for future syndication of professional investors to support both corporate and drug development activities.
Bionure has participated in the following projects. These projects have received funding from the Ministry of Science and Innovation, within the National Plan for Scientific Research, Development and Technological Innovation 2008-2011. They have been co-financed by the European Regional Development Fund (ERDF).
Bionure has received non-dilutive funding support from the following local, national and european governments:
Nuevas aproximaciones terapéuticas para la Esclerosis Múltiple y la Esclerosis Lateral Amiotrófica: efectos modificadores de la enfermedad y neuroprotección
(expediente IPT-010000-2010-035) liderado por Advanced in Vitro Cell Technologies SA y en el que también participan Neurotec Pharma SL y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.
STOP-ELA: Aproximación multi-tecnológica para el desarrollo de nuevas terapias y sistemas avanzados de administración farmacológica para la Esclerosis Lateral Amiotrófica
(expediente IPT-2011-1091-900000) liderado por Neurotec Pharma SL y en el que también participan Advanced in Vitro Cell Technologies SA, Palo Biofarma SL, Natac Biotech SL, Universidad de Zaragoza y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer
Desarrollo de terapias neuroprotectoras para Esclerosis Múltiple
(expediente IPT-2011-1312-900000) liderado por Digna Biotech SL, y en que también participan la Fundación Privada Institut d’Investigació Biomèdica de Bellvitge y el Consorci Institut d’Investigacions Biomèdiques August Pi i Sunyer.
Top-tier professionals and experts working towards a common goal
Drug discovery interest for remyelinating drugs has recently increased. However, remyelination can be futile if axons are not preserved (neuroprotection)
We look forward to pursuing partnership opportunities with industry leaders.